STAIR (Stroke Treatment Academic Industry Roundtable) recommended the use of female, hypertensive, aged, and diabetic animals in preclinical stroke research to better mimic the human stroke population. 7 The use of aged and hypertensive animals has been increasing for use in preclinical stroke Background and Purpose-Aging and hypertension, comorbidities prevalent in the stroke population, are associated with poor collateral status and worsened stroke outcome. However, underlying mechanisms by which these conditions affect stroke outcome are not clear. We studied the role of PAI (plasminogen activator inhibitor)-1 that is increased in aging and hypertension on brain and vascular expression of inflammatory factors and perfusion that may contribute to worse stroke outcomes. Methods-Aged (≈50 weeks) and young (≈18 weeks) spontaneously hypertensive rats (SHR) were subjected to ischemia by middle cerebral artery occlusion (2 hours) and reperfusion (2 hours) with or without treatment with the PAI-1 inhibitor TM5441. Changes in middle cerebral artery and collateral perfusion territories were measured by multisite laser Doppler. Reactivity to TM5441 was studied using isolated and pressurized leptomeningeal anastomotic arterioles. Brain injury was determined by 2,3,5-triphenyltetrazolium staining and quantitative immunohistochemistry of amyloid-β-42, PAI-1, and hemoglobin. Circulating inflammatory factors were measured by ELISA. Results-Changes in cerebral blood flow during middle cerebral artery occlusion were similar between groups, with both having poor collateral perfusion and incomplete reperfusion. However, aged SHR had greater brain injury versus young (41±2 versus 23±2%, P<0.05) as well as increased brain deposition of amyloid-β-42 and circulating oxLDL (oxidized low-density lipoprotein). Erythrocyte aggregation and hemorrhage within the injured brain was observed in 50% of aged but no young SHR, with increased circulating PAI-1 in this subgroup of aged SHR (16±3 versus 6±2 ng/mL, P<0.05). PAI-1 inhibition with TM5441 improved brain injury but did not affect hemorrhage. TM5441 increased collateral perfusion by 38±7% and dilated leptomeningeal anastomotic arterioles by 44±10%, which was abolished by nitric oxide synthase inhibition. Conclusions-Increased injury in aged SHR seemed to be related to poor collateral perfusion, hemorrhagic transformation, increased amyloid-β-42, and oxidative stress. PAI-1 inhibition reduced infarction in both groups of SHR that possibly due, in part, to increased collateral perfusion. Visual Overview-An online visual overview is available for this article.
M
any acute stroke patients are aged and with a history of chronic hypertension. For example, The International Stroke Trial of >17 000 patients revealed that 81.6% of patients were hypertensive and 84.1% were 60 years or older. 1 Although slightly different among clinical studies, the majority of reported average age of first-ever stroke was ≈70 years old or higher, further highlighting the large population of stroke patients that are aged. 2, 3 Not only are aging and hypertension major risk factors and comorbidities of stroke, but also patients who are aged and hypertensive have more severe stroke and worse stroke outcome, including larger infarct, and increased incidence of disability and death. 1, 4 Importantly, larger infarct is associated with greater incidence of hemorrhagic transformation, although there is no direct evidence suggesting that patients who are aged and hypertensive are more likely to have this secondary injury after acute ischemic stroke. 5, 6 Despite these epidemiological data, the effects of aging and hypertension on stroke outcome are understudied as the majority of animal stroke research uses young male animals. In 2009, the
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studies, but the combined effect of aging and hypertension on stroke outcome is still largely unknown. Both aging and hypertension are associated with increased tissue and circulating PAI-1, an endogenous serine protease inhibitor that regulates fibrinolysis, vascular fibrosis, and endothelial cell senescence that could be an important contributor to stroke and stroke outcome. Increased PAI-1 reduces tPA (tissue-type plasminogen activator)-and uPA (urokinase-type plasminogen activator)-mediated plasmin production, leading to decreased fibrinolysis that is well-known in aging. 8, 9 In addition, increased PAI-1 and decreased tPA has been found in patients with hypertension, suggesting a link between hypertension and hypofibrinolysis as well. 10 PAI-1 also seems to have a role in stroke outcome. Overexpression of PAI-1 increased brain injury in a mouse model of thrombotic stroke but not permanent middle cerebral artery (MCA) ligation, suggesting increased ischemic brain injury may be related to PAI-1-mediated increase in coagulation and subsequent reduced reperfusion. 11 In addition, inhibition of PAI-1 with an inhibitory antibody increased reperfusion, reduced infarct volume, and fibrin deposition in a mouse model of acute ischemic stroke. 12 These results demonstrate that PAI-1 inhibition may reduce ischemic brain injury through alleviating incomplete reperfusion by preventing coagulation, but it remains unknown in the setting of aging and hypertension when PAI-1 expression is high. Therefore, we studied the effect of pharmacological PAI-1 inhibition on cerebral collateral perfusion, incomplete reperfusion, and stroke outcome in aged compared with young hypertensive rats. We also investigated the role of elevated oxidative stress and chronic inflammation in aging and hypertension as they have major impacts on the cerebral circulation, neurons, and other brain cells that may be involved in worsening brain injury after MCA occlusion in aged spontaneously hypertensive rats (SHR).
13,14 Therefore, we measured mediators and markers of oxidative stress and inflammation that are known to be increased in aging and hypertension, including amyloid-β-42 protein (Aβ42), oxLDL (oxidized low-density lipoprotein), and TNF (tumor necrosis factor)-α.
Methods
The data that support the findings of this study are available on request. Please send a request to the corresponding author.
Animals
Aged male SHR (50-52 weeks old, n=12) and control young male SHR (17-18 weeks old, n=18) were used in this study. All animal procedures were approved by the Institutional Animal Care and Use Committee at the University of Vermont and complied with the National Institutes of Health guidelines for care and use of laboratory animals. Detailed animal descriptions are available in the online-only Data Supplement.
Multisite Laser Doppler Flowmetry
Dual laser Doppler probes (Perimed Inc, Ardmore, PA) were used to measure changes in cerebral perfusion in the MCA and collateral perfusion territories, as described previously.
15
Model of Transient Focal Ischemia and Treatment
A proximal MCA occlusion filament model was used, as previously described. 16 The MCA was occluded for 2 hours, followed by reperfusion for 2 hours. Some young (n=6) and aged (n=4) SHR were treated with a PAI-1 inhibitor TM5441 (Tocris, Minneapolis, MN; 5 mg/kg, IV dissolved in DMSO diluted in saline) 10 minutes before reperfusion and compared with untreated groups. Detailed experimental procedures are available in the online-only Data Supplement. 
Stroke Outcome Determinations
Determination of Circulating Oxidative Stress and Inflammatory Markers
Commercially available ELISA kits were used for determining serum levels of Aβ42, PAI-1, oxLDL, and TNF-α. Detailed experimental procedures are available in the online-only Data Supplement.
Reactivity of Isolated Leptomeningeal Anastomoses
Leptomeningeal anastomotic arterioles (LMAs) identified as distal branches between anterior cerebral arteries and MCAs were isolated and pressurized in an arteriograph bath (Living System Instrumentation, St. Albans, VT) containing circulating physiological saline solution from young SHR (n=4), as previously described.
17
LMAs were allowed to equilibrate for 1 hour at 20 mm Hg to develop spontaneous tone. Myogenic reactivity of LMAs was determined by stepwise increase in pressure from 20 to 100 mm Hg. One vessel was excluded because it did not develop sufficient spontaneous tone. Reactivity of LMAs to cumulative concentrations of TM5441 (10 −8 to 10 −5 mol/L) was tested first in the absence and then presence of Nω-nitro-L-arginine methyl ester (L-NAME, 10 −4 mol/L; Sigma, St. Louis, MO). This range of TM5441 concentration closely matched the dose in the in vivo treatment (maximum plasma concentration of 5 mg/kg TM5441 was ≈1.8×10
−5 mol/L). 18 Zero calcium physiological saline solution was used to produce maximum dilation of LMAs and calculate tone and reactivity.
Data Calculations and Statistical Analysis
Calculation for percent tone and percent reactivity in isolated LMAs was described in detail previously. 17 Results are presented as mean±SEM. Mann-Whitney or t test was used to determine statistical differences between groups where appropriate using GraphPad Prism 7 (La Jolla, CA). Repeated measures 1-way ANOVA was used for changes of cerebral perfusion versus baseline. Two-way ANOVA with a Tukey test for multiple comparisons was used for determining differences between groups. Differences were considered statistically significant at P<0.05.
Excluded Animals
A total of 5 animals (3 aged and 2 young SHR) were excluded because of insufficient drop in cerebral perfusion that was <70% during ischemia. One additional young SHR was excluded from isolated LMA studies because of insufficient tone development.
Results
Physiological Parameters During Ischemia and Reperfusion in Young and Aged SHR
Mean arterial pressures in anesthetized animals were not different between young and aged SHR (Table II in the online-only Data Supplement). Arterial blood gases, measured at the beginning, middle, and end of the experiment, were in the physiological ranges throughout the experiment and were similar between the groups (Table II in Figure 1A shows changes in MCA flow during ischemia and reperfusion. Cerebral perfusion in the core MCA territory was decreased similarly during ischemia (0-120 minutes) between young and aged SHR, suggesting similar stroke severity. During reperfusion (120-240 minutes), cerebral perfusion was below baseline in both groups, indicating incomplete reperfusion that was similar between groups. Despite similar changes in cerebral blood flow (CBF) during ischemia and reperfusion, early brain injury volume was significantly increased in aged SHR ( Figure 1B and 1C ).
Changes in Cerebral Perfusion During Ischemia and Reperfusion in Young and Aged SHR
Brain capillary density was similar between young and aged SHR ( Figure I in the online-only Data Supplement), suggesting increased brain injury volume in aged SHR was not because of capillary rarefaction in these animals. Figure 2C ). However, when quantified over the whole image, the percentage of positive Aβ42 staining was significantly increased in aged when compared with young SHR ( Figure 2D ). Circulating Aβ42 was undetectable in both groups of rats (data not shown). However, circulating oxLDL levels were significantly increased in aged versus young SHR (3.93±0.44 versus 1.85±0.32 ng/mL; P<0.05). In addition, circulating TNF-α levels were non-significantly lower in aged versus young SHR (20.7±6.6 versus 38.0±8.2 pg/mL).
Expression of Aβ42 and Circulating
Erythrocyte Aggregation, Hemorrhage, and PAI-1 Expression in Young and Aged SHR
In addition to increased ischemic brain injury volume, 50% of aged SHR had pink coloration within the injury areas 
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( Figure 3A , upper). Microscopic analysis with H&E staining showed the appearance of erythrocyte aggregation within blood vessels, suggesting red cell stasis and possibly early hemorrhagic transformation ( Figure 3A , lower). To confirm that the pink coloration was erythrocytes, we performed immunohistochemistry for hemoglobin and quantified the fluorescence in the contralateral and ipsilateral brain regions (a representative image is shown in Figure IIF in the online-only Data Supplement). Figure 3B shows that hemoglobin fluorescence was detected in the contralateral hemispheres of both young and aged SHR. In addition, there was an increase in hemoglobin in the ipsilateral hemispheres that was not different overall with aging. However, when the aged brains were stratified by pink coloration versus no coloration, there was a significant increase in hemoglobin in the brains with coloration, indicative of erythrocyte aggregation ( Figure 3C ). However, Figure  III in the online-only Data Supplement shows that hemoglobin was found outside the vasculature, suggesting at least some of the pink coloration was hemorrhage.
To determine whether erythrocyte aggregation in capillaries in aged SHR were related to increased PAI-1, we measured circulating and tissue levels of PAI-1. Figure IV in the online-only Data Supplement shows there was no difference in cerebral microvessel expression of PAI-1 between aged SHR brains with and without pink coloration. However, serum PAI-1 levels were significantly increased in aged SHR with erythrocyte aggregation versus those without ( Figure 3D ). Thus, increased circulating PAI-1 levels, but not capillary expression of PAI-1, seemed related to erythrocyte aggregation in aged SHR after stroke.
Inhibition of PAI-1 During MCA Occlusion in SHR
The increase in circulating PAI-1 in aged SHR with hemorrhage led us to hypothesize that PAI-1 was involved in the increased brain injury in aged SHR. Therefore, the small molecule PAI-1 inhibitor TM5441 was given 10 minutes before reperfusion in both young and aged SHR. One aged SHR treated with TM5441 was excluded because of insufficient drop in CBF during filament occlusion that later was determined to have a secondary M1 branch of the MCA. The remaining animals all had CBF drops that were between 78±4% and 84±3% (P>0.05 for all). Figure 4A shows that acute treatment with TM5441 decreased acute brain injury volume in both young and aged SHR. Interestingly, PAI-1 inhibition did not affect the incidence of erythrocyte aggregation in aged SHR ( Figure 4B ). Moreover, PAI-1 inhibition did not significantly affect circulating levels of oxLDL (3.93±0.44 versus 3.11±0.53 ng/mL; P>0.05) and TNF-α (20.7±6.6 versus 16.2±3.5 pg/mL) in aged SHR. In addition, treatment with TM5441 did not affect reperfusion CBF in the MCA territory that was below baseline and similar between groups (data not shown). However, TM5441 increased collateral flow in both young and aged SHR by 30% to 40% relative to before treatment when the filament was still in place ( Figure 5B ). When compared with baseline (before filament insertion), TM5441 increased collateral CBF in young from −58±8% to −45±12% (P≤0.05) and aged SHR from −43±12% to −28±17% (P=0.08).
To determine whether the increase in collateral flow by TM5441 was because of vasodilation of LMAs (pial collaterals), an isolated vessel approach was used. As published previously, isolated and pressurized LMAs from SHR had considerable myogenic tone (43±4%).
17 Figure 5C shows a representative tracing of LMA diameter changes to TM5441 in the absence or presence of L-NAME. TM5441 caused dosedependent vasodilation of LMAs that was blocked in the presence of L-NAME ( Figure 5D ).
Discussion
In this study, we used aged hypertensive rats to show that acute brain injury was significantly increased after ischemia and reperfusion when compared with their younger counterparts. Increased ischemic brain injury in aged SHR seemed to be multifactorial and was associated with increased oxidative stress, Aβ deposition, erythrocyte aggregation, and hemorrhagic transformation. Pharmacological inhibition of PAI-1 during ischemia did not prevent aging-induced erythrocyte aggregation and hemorrhage, or incomplete reperfusion, but improved collateral perfusion that likely reduced ischemic brain injury (Figure 6 ).
PAI-1 is a serine protease inhibitor that regulates fibrinolysis by inhibiting plasminogen activators tPA and uPA. 8 Circulating PAI-1 is considered a marker of aging and has been shown to be a mediator of cellular aging including vascular endothelial cells.
9,19 PAI-1 is also increased in hypertension through angiotensin type-1 receptor activation that can cause hemostatic and fibrinolytic dysregulation and worsened stroke outcome through impaired microvascular perfusion. 10, 20 A previous study demonstrated that after acute embolic stroke in rats, PAI-1 was upregulated with increased fibrin obstruction of brain capillaries as early as 1 hour into ischemia. 21 Another previous study showed that anti-PAI-1 antibody increased reperfusion CBF, reduced fibrin deposit, and ischemic brain injury measured subacutely between 6 to 24 hours of reperfusion. 12 In the present study, we found that PAI-1 inhibition reduced acute brain injury, but not hemorrhage, suggesting the decreased infarction was not related to decreasing erythrocyte obstruction of brain capillaries. Further supporting this conclusion was that reperfusion CBF was similarly low in both groups of SHR. However, we unexpectedly found that PAI-1 inhibitor TM5441 caused an increase in collateral perfusion acutely during ischemia, and dilated LMAs that was blocked by NOS inhibition.
In chronic hypertension, we have previously shown that LMAs from hypertensive rats were more constricted compared with their normotensive counterparts, suggesting collateral perfusion was limited during MCA occlusion because of vasoconstricted LMAs and increased vascular Shown also are leptomeningeal anastomoses (LMAs, black circles) between anterior (ACA) and middle cerebral arteries (MCA) that were dissected for reactivity studies. B, Change in collateral flow (probe 2) during MCAO and in response to treatment with TM5441. Both untreated young and aged spontaneously hypertensive rats (SHR) had little to no collateral flow that was increased to a similar extent with TM5441 treatment. **P<0.01 vs untreated by 2-way ANOVA with Tukey multiple comparisons test. C, Representative tracing of changes in diameter of isolated and pressurized LMAs. Addition of TM5441 caused concentration-dependent vasodilation that was prevented by nitric oxide inhibition with L-NAME. D, Graph showing % reactivity of isolated pial collaterals to TM5441 in the absence and presence of L-NAME. *P<0.05 vs without L-NAME by paired t test; n=4.
resistance. 17 Importantly, increased LMA constriction was not more severe in aged versus young SHR. 17 The findings of the present study agree with the previous finding that changes in collateral perfusion during ischemia was close to zero or below in untreated young SHR and not worse in aged SHR. Interestingly, PAI-1 inhibition with TM5441 significantly increased collateral perfusion in young as well as aged SHR by 30% to 40%. To confirm TM5441 could directly increase collateral perfusion, we measured the vasodilatory response to TM5441 in isolated LMAs. We found TM5441 significantly dilated LMAs from young SHR that was abolished in the presence of the NOS inhibitor L-NAME. Therefore, it is possible that TM5441-mediated increased in collateral perfusion was because of vasodilation of LMAs through a NO-dependent mechanism.
The effect of TM5441 on NOS to cause vasodilation is not completely understood from this study. A previous study showed that in endothelial cell culture, PAI-1 inhibition with TM5441 reduced reactive oxygen species and prevented cellular senescence. 19 Uncoupling of eNOS (endothelial NO synthase), which occurs because of decreased eNOS cofactor tetrahydrobiopterin (BH 4 ) from substrate depletion, causes production of superoxide instead of NO. BH 4 depletion and eNOS uncoupling occur with postischemic reperfusion, as well as aging and hypertension. 22, 23 Thus, it is possible that antioxidant properties of TM5441 reduced superoxide production that caused vasodilation of LMAs either directly or increasing bioavailability of NO. Regardless, the vasodilation of LMAs was consistent with this compound increasing collateral flow in the acute phase of stroke.
In addition to increasing collateral perfusion, TM5441 may reduce ischemic brain injury by exerting neuroprotective effects. Our previous study showed that Sanguinate, a PEGylated carboxyhemoglobin gas transfer agent, increased collateral perfusion similar to TM5441, but only reduced brain injury when animals were treated after 30 minutes of ischemia, but not when given after 90 minutes of ischemia. 15 In the current study, TM5441 reduced brain injury when administrated after 110 minutes of ischemia, a time point even later than Sanguinate. It is possible that TM5441 may be neuroprotective, possibly because of its ability to cross the blood-brain barrier and exert antioxidant and anti-inflammatory properties centrally. 19, 24 Another possibility of PAI-1 inhibition was to reduce neutrophil infiltration, which has been shown to cause brain injury during ischemia and reperfusion. 25 Aβ is well-known to accumulate in brain tissue and blood vessels and is involved in Alzheimer disease and vascular dementia, respectively. 26 Importantly, serine proteases (including tPA and uPA) cleave Aβ42 and is thought to be one of the mechanisms for Aβ removal. 27, 28 Thus, when tPA/ uPA are inhibited by high PAI-1 in aging, removal of Aβ is decreased. Increased Aβ42 in the brain has been shown to activate neuronal cell apoptotic pathways by increasing oxidative damage. 29, 30 In the current study, we found increased Aβ42 in brain tissue but not microvasculature. Therefore, it is possible that increased brain injury in aged SHR was partly because of increased susceptibility of neurons to ischemic injury because of high oxidative stress. Although amyloid angiopathy seemed absent in these aged hypertensive animals (Aβ42 was not increased in the vasculature), we did not measure Aβ40, which is more soluble and likely to be involved in deposition in brain vasculature. 26 Increased oxidative stress and chronic inflammation have also been shown to be important mechanisms of hypertension-and aging-related diseases. 13, 14 A recent study demonstrated that elevated aldosterone in hypertensive animals may be the cause of increased oxidative stress and inflammation. 31 oxLDL, one of the circulating markers of oxidative stress, was significantly increased in aged SHR compared with young. OxLDL has been shown to upregulate PAI-1 and therefore may possibly be a mechanism for increased circulating PAI-1 in aged SHR. 32 PAI-1 inhibition by TM5441 did not reduce circulating oxLDL levels, agreeing with the idea that oxLDL is an upstream activator of PAI-1. However, the circulating proinflammatory cytokine TNF-α was paradoxically decreased in aged SHR. Although a previous study showed an increase in circulating TNF-α during aging, circulating soluble TNF receptors p55 and p75 are also elevated in aging and may have reduced free circulating TNF-α in aged SHR. 33 There are notable limitations in this study. First, absolute CBF was not measured and has been demonstrated to be lower in aged versus young SHR. 34, 35 However, we chose to use multisite laser Doppler flowmetry to allow us to continuously monitor changes in perfusion during ischemia, treatment, and reperfusion. The drawback of this approach was that we were unable to exclude the possibility that decreased baseline CBF had an impact on worse stroke outcomes in aged SHR. Second, we studied stroke in these hypertensive animals in an anesthetized state that lowered blood pressure. . Diagram summarizing potential mechanisms of increased brain injury in aged spontaneously hypertensive rats (SHR) after middle cerebral artery occlusion (MCAO). Aged SHR have increased oxidative stress as measured by high levels of oxLDL (oxidized low-density lipoprotein) that can activate PAI (plasminogen activator inhibitor)-1 through NADPH oxidase. Increased PAI-1 could increase Aβ42 deposition through increased protease inhibition. During MCAO, impaired collateral perfusion in both young and aged SHR was increased by PAI-1 inhibition in a NO-dependent manner that likely contributed to the decrease in infarction. However, PAI-1 inhibition did not affect hemorrhage or erythrocyte aggregation in aged SHR.
Although chloral hydrate is known to have a larger effect on blood pressure than other anesthetics, we used it because pentobarbital and isoflurane are known to be neuroprotective and vasodilatory, respectively, that may profoundly impact our end point measurements. Although lower blood pressures between groups were not significantly different and therefore the potential impact of blood pressure on collateral perfusion and stroke outcomes should have been minimal.
Conclusions
Acute ischemic stroke patients who are aged and hypertensive have worse stroke outcome. Despite the majority of stroke patients having these comorbidities, the combined effect of aging and hypertension on stroke outcome is not clear because the majority of basic stroke studies have used young male animals that are usually normotensive. In the current study, the combined effect of aging and hypertension increased brain injury, including the incidence of erythrocyte aggregation and hemorrhagic transformation in a rat model of acute ischemic stroke. Increased brain injury was reduced by PAI-1 inhibition and vasodilation of LMAs and increased collateral perfusion during ischemia may be one of several mechanisms that contribute to a reduction in injury. Increased brain deposition of Aβ42 and circulating oxLDL may also have a role in worse ischemic brain injuries in aged SHR that deserves further investigation.
